ASH 2016 | Comparing ibrutinib efficacy and toxicity levels by age for patients with CLL/SLL
Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, Columbus, OH, discusses the outcomes of ibrutinib therapy by age in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Patients were enrolled on RESONATE-1 (NCT01578707) and RESONATE-2 (NCT01722487); the demographic included those younger than 65 (all in RESONATE-1), 65-75 and 75 and older. The investigation looked to see if there was any difference in either efficacy or toxicity based on age. The results showed there was no difference in terms of efficacy between the age groups. Further, within the treatment naïve cohort, toxicity was not much different between age groups either. Any differences in toxicity did not translate to patients coming off study. In previously treated patients, there was a higher incidence of adverse event-related discontinuation in older patients. There were also some toxicities that were differentially seen in older patients. Those were mostly atrial fibrillation and infectious toxicities. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
Get great new content delivered to your inboxSign up